|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1989
hormonal therapy
palliative treatment
hormone-sensitive cancers
|
|
gptkbp:atccode
|
L02 AE01
|
|
gptkbp:brand
|
gptkb:Zoladex
|
|
gptkbp:casnumber
|
120287-13-0
|
|
gptkbp:chemical_formula
|
C19 H24 N4 O4 S
|
|
gptkbp:class
|
gptkb:Hirogen
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to goserelin
|
|
gptkbp:dosage_form
|
injection
implant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
goserelin
|
|
gptkbp:interacts_with
|
anticoagulants
CYP450 inducers
other hormonal therapies
|
|
gptkbp:is_monitored_by
|
bone density
hormone levels
symptoms of hormonal imbalance
|
|
gptkbp:lifespan
|
2-4 hours
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
Gn RH agonist
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
gastrointestinal disturbances
cardiovascular events
weight gain
injection site reactions
osteoporosis
mood changes
hot flashes
decreased libido
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:used_for
|
gptkb:Oncology
gptkb:endometriosis
precocious puberty
|
|
gptkbp:bfsParent
|
gptkb:Gn_RH_agonists
gptkb:Zoladex
|
|
gptkbp:bfsLayer
|
5
|